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Abstract
The emergence and spread of antibiotic resistant pathogens poses a big challenge to policy-makers, who need to
oversee the transformation of health systems that evolved to provide easy access to these drugs into ones that
encourage appropriate use of antimicrobials, whilst reducing the risk of resistance. This is a particular challenge for
low and middle-income countries with pluralistic health systems where antibiotics are available in a number of
different markets. This review paper considers access and use of antibiotics in these countries from a complex
adaptive system perspective. It highlights the main areas of intervention that could provide the key to addressing
the sustainable long term use and availability of antibiotics.
A focus on the synergies between interventions addressing access strategies, antibiotic quality, diagnostics for low-
resource settings, measures to encourage just and sustainable decision making and help seeking optimal therapeutic
and dosing strategies are key levers for the sustainable future of antibiotic use. Successful integration of such strategies
will be dependent on effective governance mechanisms, effective partnerships and coalition building and accurate
evaluation systems at national, regional and global levels.
Keywords: Antibiotic/antimicrobial resistance, Equity, Justice, Sustainability, Systems, Pluralism
Background
The emergence and spread of bacteria resistant to exist-
ing antibiotics is of growing global concern [1]. It is
widely recognised that low- and middle-income coun-
tries (LMICs), where the majority of the world’s popula-
tion live, not only face particular challenges in
addressing antibiotic resistance but also bear a dispro-
portionate burden [2]. In these countries the spread of
resistant bacteria is facilitated by poor hygiene, contami-
nated food, polluted water, overcrowding, and increased
susceptibility to infection because of malnutrition,
chronic illness and/or immunosuppression [3]. At the
same time, factors such as the likely inappropriate use of
antibiotics and availability of substandard antibiotics are
rapidly driving resistance. In LMICs with weak health
systems, the effect of antimicrobial resistance on health
and economics is largely underestimated and incom-
pletely understood. A common feature of these countries
is the emergence of pluralistic health systems where
government provision and health markets combine and
where people obtain much of their antibiotics in un-
organised markets with a wide variety of medicine pro-
viders [4]. A particular challenge in these health systems
is the simultaneous existence of limited access to effect-
ive treatment of infections and high levels of antibiotic
use. In this paper we develop an equity/social justice
perspective which takes the conditions in low resource
settings pluralistic health systems more fully into ac-
count than hitherto has been done. We review strategies
and evidence for dealing with antibiotic resistance and
consider how inequalities in health systems may influ-
ence their sustainability.
It is increasingly accepted that addressing antibiotic
resistance requires a system perspective [5]. This is due
to the myriad of interlinked technologies, networks, mar-
kets, regulations, perceptions, norms and infrastructures
that influence antibiotic use. To be truly effective, efforts
need to include strategies that cover pharmaceuticals, food
and agriculture, human resources, financing, and informa-
tion systems by linking science to practicality [3]. For an
intervention to stand a good chance of success the rela-
tionships between diverse aspects and levels of the system
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need to be considered. The relevant system includes sup-
pliers and users of antibiotic drugs and the local, national
and global actors who influence them. Broadly conceived
interventions are likely to be more robust. Elsewhere in
health policy analysis there is increasing attention to the
complex adaptive nature of health systems [6] and the im-
portance of institutional arrangements and history which
create path dependency [7]. This makes some interven-
tions more appropriate than others in different contexts.
These perspectives imply that the systems approach rele-
vant to antibiotic use goes beyond acknowledging the
existence of a multiplicity of actors to include their per-
spectives, interests, and the multi-dimensional norms and
institutions which have developed around drug use over
significant periods of time and in the context of severe re-
source constraints and inequity. Connections between in-
dividual and collective action must also be made.
In many LMIC settings characterised by this complex-
ity one can also find strong belief in the efficacy of
antibiotics with access viewed almost as a citizen’s en-
titlement [8]. Ensuring universal appropriate access to
antimicrobials is not only a critical part of realizing the
right to health, it also raises a number of ethical chal-
lenges surrounding distributive justice, individual liberty
and the responsibility for the wellbeing of future genera-
tions. Designing interventions which are in line with/
capture different notions of entitlement and justice, es-
pecially at local and national levels, will be central to
sustainable, coherent and effective action against the de-
velopment and spread of resistance. The need for both
effective strategies to ensure improved and equitable ac-
cess to antibiotics and strategies to ensure that providers
and users are influenced to use them appropriately is at
the cornerstone of tackling antibiotic resistance in LMIC
contexts. Identifying the underlying conditions of anti-
biotic use and access presents key levers for balancing
access and appropriate use at scale. This article presents
an assimilation of the key areas for intervention and the
challenges that need to be addressed in order to achieve
just and sustainable use of antibiotics.
The objective of this article is to better understand
how we can re-think the complex system of human anti-
biotic use in pluralistic health systems and measures to
address the challenges, taking into account the condi-
tions which influence sustainability in terms of access
and long term efficacy. Although we recognise the im-
portance of a ‘One Health’ approach to tackling the
complexities of antibiotic resistance, this paper focuses
on the human health perspective and the analysis is
therefore limited accordingly.
Methods
The data for this general review were identified by a
search of PubMed (January 1966 to April 2016) as well
as bibliographic references from relevant articles, includ-
ing reviews on this subject and all selected studies. The
inclusion search terms used were ‘antibiotic’ and ‘access’
or ‘excess’ or ‘rational use’ or ‘inappropriate use’. All
relevant studies in the English-language literature that
described access and appropriate use of antibiotics were
assessed. Only studies with an explicit geographic focus
on Low and Middle Income Countries or low resource
locations were selected for use. This represented 30 % of
articles retrieved. In addition, the focus of this review is
human antibiotic use and therefore only those references
describing human use were selected.
Review
Use of antibiotics in pluralistic health systems
The use of antibiotics in a pluralistic health system is
driven by a number of social-technical dimensions, ac-
tors and factors influencing providers. The perceived
value of antibiotics has diverged from their real value
and thus created a system of use that is not always
optimum. This is largely due to the way antibiotics are
embedded in meanings, networks, markets and norms.
A common feature of pluralistic health systems is the
variety of providers of health care and drugs with asym-
metries in training, understanding, skills and varying re-
lationships with formal regulatory systems. A number of
factors, including established treatment practices and fi-
nancial incentives, influence how these providers per-
form [9]. The porous boundaries between public,
private, mission and NGO-sector providers means anti-
biotics can be accessed outside of regulatory frameworks
and can be of differing quality. Other actors that can in-
fluence how antibiotics are used and accessed include
those providing key information such as governments,
mass media, NGOs, advocacy groups, advertising agen-
cies. Patients are key actors in the health system, espe-
cially when antibiotics are available over-the-counter
with the opportunity to self-medicate patients will be in-
fluenced by time, financial factors, perceived risk, and so
forth [10].
Some pervasive beliefs and meanings have been at-
tached to antibiotics which influence how they are used
[11]. For example, the consistent promotion of antibi-
otics as part of public health programs and messaging
from pharmaceutical companies has put emphasis on
accessing antibiotics rather than on rational use. The
‘syndromic management’ approach that treats presump-
tively by trying to categorise diseases/conditions by
symptoms in the absence of better diagnostics is also
thought to be a major driver of resistance [12]. In some
cases, recommendations of mass or presumptive treat-
ment has cultivated practices where antibiotics are used
indiscriminately and/or pre-emptively as opposed to a
disease-specific manner. Their connotations of modernity
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and associations with Western medicine have also pur-
veyed a desirable status for antibiotics [10].
Interventions and the complex adaptive system
Policy makers are developing National Action Plans
based on the WHO Global Action Plan approved at the
68th World Health Assembly. Whilst country-specific
interventions will be needed there are a number of simi-
larities when considering the key levers of intervention
for pluralistic health systems. How countries provide ac-
cess to efficacious antibiotics whilst ensuring rational
use for future sustainability requires simultaneously tar-
geting several key drivers and the underlying causations
within a complex system. Figure 1. provides a system
perspective of the manifold drivers of antibiotic resist-
ance in community settings of pluralistic health systems
and highlights the potential levers for intervention.
The following subsections outline some of the key
themes that arise when considering possible interven-
tions to tackle antibiotic resistance at the community
level, along with the barriers and challenges that need
to be addressed in order to develop sustainable
interventions.
Access strategies
How should the flow of antibiotics be controlled in a
system? Current thinking proposes interventions such
as, restriction of formularies, exclusive vendor availability,
requirement of preauthorisation of antibiotic use, and de-
escalation of broad-spectrum coverage when a pathogen
is identified [13, 14]. It will be especially important to en-
sure the perspective of the end user in considered, par-
ticularly the most under-served, within a system of
controlled distribution and use of a new antibiotic. There
is indeed a paucity of information regarding the extent of
access to efficacious antibiotics in various localities. An
understanding of the interplay of logistical, environmental,
financial and social drivers behind current access patterns
is a key component of developing more controlled access
strategies. Effective collective action needs to be under-
pinned by a consensus on the need for action and a belief
that measures taken are just [15]. In some cases, a policy
tension might arise between saving lives with short-term
mass campaigns that advocate antibiotics, and increased
mortality as a result of increased antibiotic resistance.
Learning from success stories in other countries will be an
important part of developing effective and innovative
interventions.
Central to the discourse on treatment options is the
overall availability of antibiotics which determines the
access that people have. Rises in the availability of low
cost generic drugs have been shown to lead to increased
consumption of antibiotics, with beneficial health out-
comes [16]. However, it has also contributed to the
emergence and spread of bacterial resistance to antibi-
otics. In some cases, it has encouraged the use of old
Fig. 1 A complex system: human drivers of antibiotic resistance in pluralistic health systems
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drug products with very poor oral bioavailability, mar-
keted with historical dosage regimens and extensively
excreted in the environment. New business models are
needed in human and veterinary health that make good
quality and eco-friendly antibiotics available at an afford-
able price. Also new approaches are needed to encour-
age the development of new and innovative products
that will be required to meet the therapeutic needs of
the veterinary community while being consistent with
public health concerns.
Quality
Beyond the harmful effects for patients, substandard
medicines favour the emergence of bacterial resistance
with a worldwide impact. Despite regulatory efforts, it is
clear that substandard medications continue to be a
major concern [17]. Substandard medicines from ap-
proved manufacturers still reach the market in relatively
high volumes even when there are stringent quality as-
surance methods in place such as the WHO prequalifi-
cation program. It is also difficult to pinpoint whether
low quality manufacturing or poor storage conditions
are responsible for the substandard quality of the medi-
cations. Several studies have found that location of pur-
chase was an important indicator of quality as the failure
rate for medications purchased from an unlicensed out-
let was much higher than for those purchased from a li-
censed outlet [18, 19].
Ensuring access to antibiotics that are of an efficacious
quality is of paramount importance when considering
measures to foster just and sustainable access to antibi-
otics and how interventions to improve access will im-
pact the quality of these medicines. Adequate regulatory
capacity will need to be provided in all settings to ensure
this. Equally important in the efforts to reduce the
prevalence of substandard and counterfeit medications is
the development of accurate yet low-cost testing mecha-
nisms that can be easily applied in low-resource settings.
An important distinction between issues of quality due
to substandard storage or manufacturing and the issue
of counterfeit medications is also essential to ensure the
context of the problem is not conflated with discussions
on intellectual property law [20].
Decision making and help seeking: changing patterns
of use
In exploring strategies for improving the use of anti-
biotic drugs it is useful to analyse the health system as a
knowledge economy, which makes the benefits of expert
medical knowledge and specialised commodities, such as
drugs, widely available [7]. An important characteristic
of the health knowledge economy is the asymmetry in
knowledge between experts and the people who rely on
their advice.
Considering what determines human behaviour, and
how we explain that behaviour are helpful questions
to guide understanding what motivates people to
modify their behaviour and to accept suggestions for
modification. Behaviour change should be viewed
from all aspects of antibiotic prescribing, dispensing,
use, and handling and also understanding the causes
that lead to unnecessary use of antibiotics. We iden-
tify five levels of factors that influence antibiotic use:
1) Individual—knowledge, attitudes, beliefs, and per-
sonality; 2) Interpersonal—social identity, support,
roles; 3) Institutional—rules, guidelines, regulations, and
informal structures; 4) Community—social networks,
norms; and 5) Public policy—regulations and laws [21].
On the demand side, self-medication by consumers
with antibiotics purchased without a prescription is
common. Consumers have positive attitudes towards an-
tibiotics, but paradoxically they have poor knowledge
about these drugs and diseases [22]. The availability of
antibiotics without prescription—an important enabling
factor—mainly results from absence of prescription-only
regulation, ineffective law enforcement, practices driven
by poverty, culture, and norms [23]. Sub-optimum com-
pliance in use, including taking leftover antibiotics from
previous treatment courses and sharing unused drugs
with other people, is common in both developed and de-
veloping countries [24]. Ideally, consumers should have
access to accurate information on antibiotics and infec-
tious diseases instead of access to antibiotics without
prescription. When irrational use of antibiotics repeat-
edly happens among the public and health professionals,
it becomes the norm. To break this pattern, antibiotic
stewardship programmes should focus not only on ap-
propriate use, but also on ensuring sustainability of be-
havioural change at all levels of the system and
reorientation of social and institutional norms [5]. Solu-
tions need to focus on multifaceted and multilevel inter-
ventions that define local barriers and beliefs, which can
vary widely between cultures, countries, and regions.
Education of all health-care workers, laboratory staff,
veterinarians, and the public on appropriate antibiotic
use and antibiotic resistance is essential, and educa-
tional strategies have recently been reviewed [25]. Al-
though education alone might not be powerful
enough as an intervention, it generates knowledge
that is essential for health-care workers to understand
and support the resistance control programmes. Edu-
cation should be tailored and started early on to
shape behaviour rather than having to change it. The
potential benefits of using mobile health technologies
(mHealth) in the transmission of health behaviour
messaging, in addition to its use for tracking, report-
ing, messaging and the surveillance of resistance,
needs to be explored further [26].
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On the supply side, physicians are often role models
for other health professionals and patients who learn
how to use antibiotics from their prescriptions. Apart
from medical training, physicians are influenced by their
peers, and perceived demands of patients. Therefore,
physicians might find it difficult to comply with treat-
ment guidelines [11]. These barriers to compliance
should be removed or minimised, and options for alter-
native actions for guideline compliance should be simul-
taneously provided. Examples of options for non-
antibiotic treatment in viral or self-limiting infections
are the prescription of herbal medicines, as opposed to
antibiotics and use of a delayed prescription technique
with explicit instructions for patients about when to use
antibiotics [27]. To encourage guideline compliance,
consequences of irrational use of antibiotics should be
reframed to be relevant to the self-interest of prescribers
and institutions. Motivational measures include pay-for-
performance policy [27], the audit-feedback mechanism
on antibiotic prescribing rates of individual prescribers
[28], and public disclosure on antibiotic prescribing rates
of each health-care facility or area [3]. Major challenges
arise when antibiotic prescriptions are a source of rev-
enue for individuals or institutions, either by a fee-for-
service remuneration scheme [29] or drug-promotion in-
centives [30]. A recent Cochrane systematic review on
the comparison of educational and persuasive versus re-
strictive methods for improving antibiotic prescribing
demonstrated that on average, restrictive methods were
three times more effective than persuasive interventions
[31]. Prescribers and manufacturers also need to be
aware that studies have shown a mismatch between anti-
biotic pack sizes and guideline recommendations for
their duration is contributing to antibiotic resistance in
the community. This opens up the potential need for
more effectively designed packaging to combat resist-
ance [32].
Therapeutic and dosing strategies
Antibiotic resistance presents a major scientific chal-
lenge; not only in developing potential new treatments
and monitoring patterns of resistance but also in under-
standing the best protocols for treatments [33]. Even if
new antibiotics are developed a re-evaluation of the best
therapeutic models to employ in order to preserve and
or enhance the antibacterial effects of available drugs
will be necessary. Assumptions have been made on the
best practices for prescribing and treating bacterial in-
fections using antibiotics which are now beginning to be
challenged [34]. The way therapies prescribed needs to
be based on the most accurate data and scientific under-
standing in all population settings.
Therapeutic strategies are a much needed area of fur-
ther research. In many cases, symptoms should guide
the length of treatment, except for particular diseases
where symptoms do not reflect the true pathogen load.
In terms of treatment, emerging thoughts focus on the
need to reassess the public health message surrounding
the ideal duration of an antibiotic course; evidence
shows that many infections clear with less than a typical
course of antibiotics. Conversely, there are also argu-
ments for using more aggressive doses to reduce the sur-
vival of resistant bacteria [35]. Promotion of sequential
use, cycling strategies or mixing of different antibiotics
have all demonstrated positive effects on the reduction
of antimicrobial resistance [36]. There is also a need to
look more thoroughly at the scientific and a societal
perspective of drug combinations as opposed to mono-
therapy use to effectively combat the drug resistance
phenotype - taking the lead from successful efforts seen
with HIV and malaria therapies [37]. Several practical-
ities present challenges to implanting combination ther-
apies, many of which have arisen in the case of malaria.
These include the selection of drugs based on cost, ease
of administration, acceptability, current levels of resist-
ance, impact of combinations of drugs with mismatched
half-lives, how the drugs are used (co-administration,
co-formulation, duration, costs, understanding of re-
gimes etc, cycling) and the economics of combination
drug therapy [38].
As a first step, the global scientific community will
need to strengthen its assessment of appropriate usage,
defining parameters for deciding which antimicrobials
are effective in which areas of the world and useful at
various levels of health care systems. This is an
evidence-based normative process, and is reflected in
the development of previous effective antimicrobial pro-
grams. Furthermore, this is not a static effort, but needs
to be continuously reviewed and updated based on dy-
namics of use and evidence of emerging resistance.
Diagnostics
Diagnostic tests play a major role in the detection of
specific pathogens, discovery of new pathogens, deter-
mining appropriate therapy, monitoring response to
therapy, assessing prognosis, and disease surveillance at
the local, regional and national level [39]. Despite the in-
creased use of rapid tests and the availability of molecu-
lar and proteomics-based tests, diagnostics are not being
integrated into clinical care optimally [40]. Many pa-
tients with suspected infections receive empiric anti-
microbial therapy rather than appropriate therapy
dictated by the rapid identification of the infectious
agent. The result is over use of a small inventory of ef-
fective antimicrobials. Similarly, the reliance on syn-
dromic algorithms for treatment, whilst successful in
many cases, can encourage over-treatment and expose
patients unnecessarily to antibiotics [12]. Improved
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diagnosis relying on part technology and part syndromic
management can reduce uncertainty about whether to
treat with antibiotics or not.
Consistent with the universal health coverage strategic
direction of improving efficiency in service delivery
through improved technology, taken to scale, the advent
of simple diagnostic tests could help reduce the need for
mass administration of antibiotics and enable more pre-
cise prescription in many cases. The rapid and accurate
establishment of a microbial cause is fundamental to
quality care. New tests are needed that can identify a
specific pathogen or at a minimum, distinguish between
bacterial and viral infections, and also provide informa-
tion on susceptibility to antimicrobial agents. There is
no consensus on the type of diagnostics research and de-
velopment should aim for [41]. When new diagnostic
tests are developed, clinical factors and investigations on
effectiveness in terms of antibiotic resistance, antibiotics
use, or patient outcomes are less emphasized in their as-
sessment in favour of efficacy considerations. The local
context matters; there is also lack of clarity about how
LMICs might take up these new diagnostic tests, in the
context of different speed, robustness of system, cost, or
user-friendliness [42]. In the meantime, existing, simple
tests are still not widely used. However, there are signifi-
cant challenges to the development, regulatory approval,
and clinical integration of diagnostic tests that use these
new technologies [43]. There is a key opportunity for
private, non-profit and academic institutions to collabor-
ate on this issue.
Affordability
A key element in getting access to care to the commu-
nity will be the affordability of the antimicrobials [44].
Principles of both stewardship and global solidarity sug-
gest that pricing and financing of novel antimicrobials at
the national and subnational level must be undertaken
with an eye towards innovative mechanisms [45]. There
is a need to reduce the financial burden of health care in
general on poor families, as emphasised in universal
health coverage strategies. When considering the na-
tional schemes of government provided health insur-
ance, measures to reduce the cost of antimicrobials to
patients need to be complemented by actions to ensure
these drugs are used appropriately, therefore coupled
with treatment guidelines, effective monitoring and sur-
veillance and alleviating perverse incentives.
In many pluralistic health systems the reliance on in-
formal providers for antibiotics will mean the provision
of universal health insurance will take time to be effect-
ive, therefore other measures will have to temporarily
ensure access to effective treatments is increased. One
option is for government, donor agencies and/or philan-
thropic organisations to reduce the cost of antimicrobials
through more effective procurement from manufacturers
and/or supplying drugs at a subsidised price [46].
With funds being allocated to the research and devel-
opment of new antibiotic therapies in high-income
countries we are likely to also see the limitation of new
therapies to preserve their efficacy. Therefore a matching
of funds needs to be prioritised for measures to increase
appropriate access to common treatments globally. Such
as, funding measures to reduce financial barriers to ac-
cess, but also reducing exposure to infection and suscep-
tibility to infections. This type of combined investment
strategy is essential to garner wide political support,
otherwise preventing the production and commercial
use of any new therapies will be difficult [47].
Governance
The implementation of a sustained effort to achieve
system-wide changes in the use both of existing, effect-
ive antibiotics and future, new antibiotics requires in-
formed and committed collaboration at national and
global levels [48]. In May 2015 the WHO released a glo-
bal action plan on antibiotic resistance, but it remains to
be seen whether effective global governance institutions
can be created. There are numerous initiatives currently
being conducted by various stakeholders and from dif-
ferent perspectives. Currently, there is no analysis as to
how the host of initiatives function cohesively at the glo-
bal level. New coordination and financing mechanisms,
some of which must be organized globally utilizing glo-
bal governance instruments and mechanisms are essen-
tial to tackling AMR. Although tracking progress on
antibiotic resistance containment must be a prerogative
of each national government, it is vital to develop
monitoring and evaluation frameworks that allow for
information sharing between countries regionally and
globally.
Effective governance of antibiotics is key to the sus-
tainable access and use challenge, this will involve effect-
ive regulation, the involvement of all actors and effective
markets. National level political commitments, frame-
works and institutions are also important [21]. For ex-
ample, the creation of a high-level task force to oversee
national efforts contributed to Sweden’s success in limit-
ing antibiotic use [49]. Countries that have implemented
comprehensive national strategies have been the most
successful in controlling resistance [50]. Additionally,
countries with cases of antibiotic resistance have found a
targeted national approach successful eg, the UK for
control of MRSA and Clostridium difficile [51] and the
USA has implemented various initiatives [52]. However,
these programmes need time and patience to be set up
and need to be backed by visionary governments with
adequate funding. A stepwise approach to a national
strategy according to a contextualised and prioritised
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road map might be the best way forward for most set-
tings. In resource-poor countries, there has been much
less progress, although China, Vietnam and India not-
ably have made important steps recently [53].
Barriers to the implementation of effective and sus-
tainable programmes exist in many regions of the world.
The bottlenecks for implementing stewardship in both
resource rich and poor countries are often strikingly
similar, largely as a result of insufficient leadership, com-
mitment, and funding [54]. One major challenge in
countries with weak management and governance struc-
tures is to involve powerful organisations in partnership
arrangements, while protecting the interests of the
relatively poor and powerless [48]. For example, pharma-
ceutical companies could make a substantial contribu-
tion towards improving antibiotic use but there is a
tension between their search for short-term profits and
the longer-term benefits of ensuring they are only used
when needed. This raises questions about the degree to
which large companies can be made accountable to local
stakeholders and the potential role of global agreements
on standards of behaviour. The increasing global pres-
ence of companies from rapidly growing middle-income
countries and the consequent involvement of their gov-
ernments in governance arrangements is creating an-
other level of complexity, since these important global
actors are concurrently building institutions to make
their own pluralistic health systems more coherent. Gov-
ernments have a key leadership role in overseeing the
creation and oversight of these institutions. This may
work better if other strong actors, who can express the
interests of the different stakeholders, are involved.
These could be strong NGOs, citizen organisations, faith
based organisations, professional associations and so
forth. There is limited evidence about the approaches
that work well in building institutions in low and
middle-income countries [55], however, exploring the
possibilities of innovative partnerships will be key in
tackling AMR. Acknowledging the presence of informal
providers of drugs and services in LMICs and develop-
ing ways of creating “safer informality” will be essential
in creating truly effective and representative partner-
ships. Key to governance will be consensus and coalition
building amongst stakeholders; building shared visions
of just and sustainable use and understanding and ap-
peasing areas of competing interest.
Sustainable future solutions in a complex world
Effective interventions will need to consist of a package
of components – one approach is unlikely to suit all set-
tings [56]. Based on the potential areas of intervention
discussed above a number of key challenges and areas
for further research present themselves. Table 1 provides
an overview of the themes, rationale and variables that
need to be explored in order to develop sustainable fu-
ture access and appropriate use interventions for antibi-
otics. A number of possible interventions have an
apparent simplicity, but in fact, they influence complex
medical and evolutionary landscapes, that is they might
result in many other effects, variable in different places
and some of them eventually unwanted. Apparently
‘simple’ interventions are frequently complex and unpre-
dictable in their effects [57]. Complexity influences
interventions not only because of the number of inter-
acting components, but also because of the number and
difficulty of behaviours required by those delivering or
receiving the intervention [58]; the number of groups or
organizational levels targeted by the intervention [59],
the number and variability of outcomes; and the degree
of flexibility or tailoring of the intervention permitted
[60]. A combination of synergistic interventions tailored
to the wider ecological context and specific circum-
stances with the requisite monitoring of outcomes is
likely the most efficient approach.
The idea of antibiotic mainstreaming, i.e. - always to
consider the effects of various types of interventions and
various types of decisions on future availability of antibi-
otics, could be a means to raise awareness and integrate
potential behaviour modification with respect to antibi-
otics in all aspects of society [21].
Conclusions
Antibiotics are different from all other medicines in that
the effects of their use extend beyond individual pa-
tients. The societal effects of antibiotic use justifies that
measures need to ensure they should be accessed, pre-
scribed, dispensed and used appropriately and accurately
based on robust scientific evidence. In order to create
sustainable future solutions for just access and appropri-
ate use of antibiotics interventions need to reflect the
complex adaptive system of antibiotic use and availabil-
ity. When considering this multi-tiered system, set
within broader epidemiological and ecological contexts,
the potential areas for synergy and conversely the poten-
tial unintended consequences need to be considered.
With deeper understanding a number of key themes
present opportunities for intervention: access strategies,
measures to ensure the quality of antibiotics, measures
to encourage just and sustainable decision making and
help seeking, effective therapeutic and dosing strategies
and the use of accurate diagnostics. The achievement of
progress towards adopting and integrating interventions
hinges on effective partnerships and coalition building,
accurate evaluation systems and effective governance
mechanisms. The activities of a large number of stake-
holders will need to be aligned. This will involve new
kinds of partnerships, a deliberative process bringing in
different voices reflecting the complexity of the issue.
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Such partnerships will require a balance of interests and
belief that the benefits of partnership outweigh any
losses. Partnerships will need to exist at regional, na-
tional and global levels and involve public, private, for-
mal and informal sectors and will likely go beyond
traditional health system boundaries. In many settings
this will present challenges and feasibility will vary in
different settings. There are indeed many gaps and chal-
lenges in the current understanding of antibiotic access
and use, but identifying the levers for change as part of a
wider system clearly identifies areas for immediate ac-
tion and ways to engender a long-term sustained change
for antibiotic access and use.
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Table 1 Variables to explore for sustainable future access and appropriate use interventions
Theme Rationale Variables to explore for intervention
Access strategies How should antibiotics be made available to all
members of a community?
Roll out options, referral patterns, training community
health workers to prescribe appropriately, exclusive
vendor availability
Antibiotic quality Measures to ensure antibiotic quality Roles of different actors, effective technologies for
low resource settings, drivers of quality
Decision making and help seeking
(unlocking capabilities)
Strategies to enable people to treat infections
when necessary while reducing risks of resistance
Suppliers of advice and drugs, role of financial
incentives, assessment of risk and need, professional
and social norms, understandings of disease and
antibiotics, ideas of entitlement, design of packaging
Therapeutic and dosing strategies Optimising drug use strategies based on the
scientific, economic, social and epidemiological
context
Explore antibiotic combinations, co-administration,
co-formulation, cycling, best practice for frequency
and adherence to dosing strategies
Use of diagnostics How can diagnostics improve diagnosis and
treatment and be relevant in low resource settings
Dual diagnosis of infection and resistance in low
resource settings, meeting the needs of populations,
integration with surveillance, effects on access to care,
treatment-seeking behaviour or supply stock-outs,
prescription/antibiotic use
Exploring integration of new strategies Transmission of health behaviour messaging
integration of appropriate use measures into
everyday practices. Explore innovative ways of
tracking, diagnosis, treatment, reporting, messaging
and the surveillance of resistance and antibiotic use
How can mobile health technology be incorporated
to improve diagnosis, treatment and surveillance;
can social media be used to encourage appropriate
use of new/existing therapies; role of pharmaceutical
companies and appropriate use
The role of markets and market actors Effective strategies for involving players at every
level in the market (local, national, regional,
international) and aligning incentives
Roles/responsibilities for information transmission,
guideline adherence, positive incentive creation,
measures to improve access and reduce resistance
Consensus and coalition building Building (and negotiating) shared visions of just
and sustainable use
Mapping competing understandings and interests of
relevant organisations and associations; Building of
coalitions for change
Governance Effective mechanisms at the community and
regional level for ensuring sustainable access and
use of antibiotics
Agreed roles and responsibilities, effective funding
streams, harmonisation where possible
Evaluation of systems Observe impact of interventions Other health consequences, clinical outcomes of AMR,
resistance in the environment, health seeking behaviour
and wider social consequences (economic, networks)Identify unintended consequences
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